Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program

Riad El Fakih, Hildegard Greinix, Mickey Koh, Bronwen Shaw, Mohamad Mohty, Mohammad Al Nahedh, Wael Saber, Mohamed A. Kharfan-Dabaja, Miguel Angel Perales, Bipin N. Savani, Navneet S. Majhail, Jakob R. Passweg, Anna Sureda, Syed Osman Ahmed, Eliane Gluckman, Marcie Riches, Areej El-Jawahri, Damiano Rondelli, Alok Srivastava, Lawrence FaulknerYoshiko Atsuta, Karen K. Ballen, Walid Rasheed, Shinichiro Okamoto, Adriana Seber, Nelson Chao, Nicolaus Kröger, Yoshihisa Kodera, Jeff Szer, Shahrukh K. Hashmi, Mary M. Horowitz, Daniel Weisdorf, Dietger Niederwieser, Mahmoud Aljurf

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Establishing a hematopoietic cell transplantation (HCT) program is complex. Planning is essential while establishing such a program to overcome the expected challenges. Authorities involved in HCT program establishment will need to coordinate the efforts between the different departments required to start up the program. One essential department is pharmacy and the medications required. To help facilitate this, the Worldwide Network for Blood and Marrow Transplantation organized a structured survey to address the essential medications required to start up an HCT program. A group of senior physicians and pharmacists prepared a list of the medications used at the different phases of transplantation. These drugs were then rated by a questionnaire using a scale of necessity based on the stage of development of the transplant program. The questionnaire was sent to 30 physicians, in different parts of the world, who have between 5 and 40 years of experience in autologous and/or allogeneic transplantation. This group of experts scored each medication on a 7-point scale, ranging from an absolute requirement (score of 1) to not required (score of 7). The results are presented here to help guide the prioritization of required medications.

Original languageEnglish (US)
Pages (from-to)267.e1-267.e5
JournalTransplantation and Cellular Therapy
Volume27
Issue number3
DOIs
StatePublished - Mar 1 2021

Bibliographical note

Funding Information:
Financial disclosure: none. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: Riad El Fakih and Mahmoud Aljurf wrote the first draft. The draft was edited by all the co-authors. The authors vouch for the accuracy of the data and have approved the final version for submission for publication.

Publisher Copyright:
© 2020

Keywords

  • Essential medications
  • Hematopoietic cell
  • Required medications
  • Transplantation program
  • WBMT

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program'. Together they form a unique fingerprint.

Cite this